1. 1) Andrews PL, Rapeport WG, Sanger GJ. Neuropharmacology of emesis induced by anti-cancer therapy. Trends Pharmacol. Sci., 9, 334–341 (1988).
2. 2) Cubeddu LX, Hoffmann IS, Fuenmayor NT, Finn AL. Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting. N. Engl. J. Med., 322, 810–816 (1990).
3. 3) Kumakura H, Koyanagi J, Nishioka Y, Sato M, Nakajima T, Nakahira K, Tateno M. Phase I Study of Granisetron (Second Report)—Pharmacokinetics of Granisetron following Single and Repeat Intravenous Drip Infusion in Japanese Healthy Volinteers—. Rinsho Iyaku, 6 (Suppl. 5), 25–34 (1990).
4. 4) Carmichael J, Cantwell BM, Edwards CM, Zussman BD, Thompson S, Rapeport WG, Harris AL. A pharmacokinetic study of granisetron (BRL 43694A), a selective 5-HT3 receptor antagonist: correlation with anti-emetic response. Cancer Chemother. Pharmacol., 24, 45–49 (1989).
5. Clinical Evaluation of Antiemetic Effects of 5-hydroxytryptamine Receptor type 3 (5HT3 Receptor) Antagonists Based on Changes in Eating Condition in Cancer Patients Receiving Chemotherapy